Gilead Sciences
Generated by Llama 3.3-70BExpansion Funnel Raw 71 → Dedup 30 → NER 21 → Enqueued 18
| Gilead Sciences | |
|---|---|
 | |
| Name | Gilead Sciences |
| Type | Public |
| Traded as | NASDAQ: GILD |
| Industry | Biotechnology |
| Founded | 1987 |
| Founder | Michael L. Riordan |
| Headquarters | Foster City, California |
Gilead Sciences. Gilead Sciences is a biotechnology company that focuses on the discovery, development, and commercialization of pharmaceuticals for the treatment of HIV, hepatitis, influenza, and cancer. The company was founded in 1987 by Michael L. Riordan and has since become a leading player in the biopharmaceutical industry, with collaborations with Johnson & Johnson, Pfizer, and Merck & Co.. Gilead Sciences has also partnered with World Health Organization and Bill and Melinda Gates Foundation to increase access to its HIV treatments in developing countries.
● History
Gilead Sciences was founded in 1987 by Michael L. Riordan, with the goal of developing antiviral medications for the treatment of HIV and other viral diseases. In the early 1990s, the company began to develop its first HIV treatment, tenofovir, in collaboration with University of California, San Francisco and National Institutes of Health. The company's early success was driven by the approval of tenofovir by the US Food and Drug Administration in 2001, which was followed by the approval of emtricitabine in 2003. Gilead Sciences has also acquired several companies, including NeXstar Pharmaceuticals and Myogen, to expand its portfolio of pharmaceuticals and biologics. The company has received awards from Fortune (magazine) and Science (journal) for its innovative approach to drug development.
● Products
Gilead Sciences has a diverse portfolio of pharmaceuticals and biologics for the treatment of various diseases, including HIV, hepatitis, influenza, and cancer. The company's leading products include Truvada, Atripla, and Complera, which are used to treat HIV in combination with other antiretroviral medications. Gilead Sciences has also developed Sovaldi and Harvoni for the treatment of hepatitis C, in collaboration with University of Texas at Austin and Duke University. The company's influenza treatment, Tamiflu, was developed in partnership with Hoffmann-La Roche and World Health Organization. Gilead Sciences has received approvals from European Medicines Agency and US Food and Drug Administration for its products, which are marketed in United States, Europe, and Japan.
● Research and Development
Gilead Sciences has a strong commitment to research and development, with a focus on the discovery and development of new pharmaceuticals and biologics for the treatment of various diseases. The company has established partnerships with Stanford University, University of California, Berkeley, and Massachusetts Institute of Technology to advance its research and development efforts. Gilead Sciences has also collaborated with National Cancer Institute and National Institute of Allergy and Infectious Diseases to develop new treatments for cancer and infectious diseases. The company's research and development pipeline includes several promising candidates, including bictegravir and filgotinib, which are being developed for the treatment of HIV and inflammatory diseases. Gilead Sciences has received funding from National Institutes of Health and Bill and Melinda Gates Foundation to support its research and development efforts.
● Financials
Gilead Sciences is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol GILD. The company has a market capitalization of over $80 billion and generates annual revenues of over $20 billion. Gilead Sciences has a diverse revenue stream, with a significant portion of its revenues coming from the sales of its HIV treatments, including Truvada and Atripla. The company has also generated significant revenues from the sales of its hepatitis C treatments, including Sovaldi and Harvoni. Gilead Sciences has a strong financial position, with a significant cash reserve and a low debt-to-equity ratio. The company has been recognized by Fortune (magazine) and Forbes as one of the most profitable and successful companies in the biotechnology industry.
● Controversies
Gilead Sciences has been involved in several controversies over the years, including criticism of its pricing practices for its HIV and hepatitis C treatments. The company has been accused of charging high prices for its medications, making them unaffordable for many patients in developing countries. Gilead Sciences has also faced criticism for its patent practices, including the use of patent evergreening to extend the patent life of its medications. The company has been involved in several high-profile lawsuits, including a lawsuit with Merck & Co. over the patent rights to its hepatitis C treatment, sofosbuvir. Gilead Sciences has also faced criticism from Medecins Sans Frontieres and Doctors Without Borders for its failure to provide affordable access to its HIV treatments in developing countries.
● Corporate Affairs
Gilead Sciences is headquartered in Foster City, California, and has operations in United States, Europe, and Asia. The company is led by a team of experienced executives, including Daniel O'Day and Andrew Dickinson. Gilead Sciences has a strong commitment to corporate social responsibility, with a focus on increasing access to its medications in developing countries. The company has established partnerships with World Health Organization, Bill and Melinda Gates Foundation, and Clinton Foundation to support its corporate social responsibility efforts. Gilead Sciences has received recognition from Fortune (magazine) and Corporate Knights for its commitment to corporate social responsibility and sustainability. The company has also been recognized by Human Rights Campaign and GLAAD for its commitment to LGBTQ+ rights and diversity and inclusion.